A primer on HELIOS-B, an enormous stock-moving event for Alnylam Pharmaceuticals

This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

The outcome of the HELIOS-B study — expected at the end of June or early July — is an enormous stock-moving event for Alnylam Pharmaceuticals. Billions of dollars in potential revenue — sufficient to power Alnylam into profitability — are on the line.

The results will also impact competitors, including BridgeBio Pharma and Ionis Pharmaceuticals.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region – Biotech Investments

EQS-News: Formycon AG / Key word(s): Agreement MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA

May 16, 2024

House committees strike deal on health transparency, PBM reform package

WASHINGTON — Republicans on three key House committees have reconciled their differing legislative packages to increase transparency in the health care system and reform payment

September 6, 2023

A better way for doctors and health plans to manage genetic tests

New technology has a history of overwhelming existing systems that try to manage it, and that’s proving to be the case with genetic testing and

October 19, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.